Przedsiebiorstwo Produkcji Farmaceutycznej Hasco-Lek Spólka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Przedsiebiorstwo Produkcji Farmaceutycznej Hasco-Lek Spólka AkcyjnafiledCriticalPrzedsiebiorstwo Produkcji Farmaceutycznej Hasco-Lek Spólka Akcyjna
Priority to PL396706ApriorityCriticalpatent/PL222738B1/en
Publication of PL396706A1publicationCriticalpatent/PL396706A1/en
Publication of PL222738B1publicationCriticalpatent/PL222738B1/en
Kompozycja farmaceutyczna lub kosmetyczna do stosowania miejscowego zawiera heparyne, lewomentol i diosmine oraz liposomy. Sposób otrzymywania kompozycji farmaceutycznej lub kosmetycznej do stosowania miejscowego w formie zelu polega na tym, ze do alkoholu, w którym rozpuszczono konserwanty, wprowadza sie fosfatydylocholine i lewomentol oraz kompozycje zapachowa, a nastepnie miesza sie z nim stabilizator i heparyne rozpuszczone w wodzie, po dokladnym uwodnieniu fazy organicznej dodaje sie diosmine calosc homogenizujac, nastepnie dodaje sie substancje zelujaca i ponownie calosc sie homogenizuje, na koniec dodaje sie regulator pH i calosc dokladnie sie miesza i odpowietrza.The topical pharmaceutical or cosmetic composition contains heparin, levomenthol and diosmine as well as liposomes. The method of obtaining a pharmaceutical or cosmetic composition for topical application in the form of a gel consists in introducing phosphatidylcholine and levomenthol and fragrance into the alcohol in which the preservatives have been dissolved, followed by mixing with stabilizer and heparin dissolved in water after thorough hydration. the organic phase, diosmine is added homogeniously, then the gelling agent is added and the whole homogenized again, finally a pH regulator is added and the whole is thoroughly mixed and bled.
PL396706A2011-10-192011-10-19The pharmaceutical or cosmetic composition and the production method thereof
PL222738B1
(en)
method for preparing a pharmaceutical hemostatic liquid foam, product combination, transient pharmaceutical hemostatic liquid foam, kit for producing a transient pharmaceutical hemostatic liquid foam, and, use of a pharmaceutical preparation
Antibody that binds to human or cynomolgus complement protein c3b; pharmaceutical composition, nucleic acid, vector and host cell comprising said antibody; use to treat age-related macular degeneration.
Simple variable domain (dab) of immunoglobulin anti-vascular endothelial growth factor (vegf); nucleic acid encoding it; vector and host cell; method of production; vegf antogonist comprising the dab; composition comprising antogonist; and use of the antagonist to prepare a medicament.
composition comprising uniform, rigid, spherical, nanoporous calcium phosphate micro-sized particles and method for combining and separating the non-aqueous solvent from said particles
immunogenic composition, use of an immunogenic composition, process for preparing an immunogenic composition, method for making a stable immunogenic composition, and kit
a method for the preparation of a microvesicle bearing tf having procoagulant activity, microvesicles hampered by said method and their use, as well as a pharmaceutical composition and kit comprising them.
Immunomodulatory composition comprising a vehicle for administration of cationic liposome and a nucleic acid molecule; and its use to treat a bovine respiratory disease in cattle.